Loading...
•
Mar 31, 2022
Immunome Q1 2022 Earnings Report
Immunome reported financial results for Q1 2022.
Key Takeaways
Immunome reported on its progress with IMM-BCP-01 for COVID-19 treatment, which received FDA clearance for a Phase 1b clinical trial, and IMM-ONC-01, an antibody treatment targeting IL-38, with an IND submission targeted for the second half of 2022.
Received FDA clearance for Phase 1b clinical trial of IMM-BCP-01 for COVID-19 treatment.
Patient recruitment efforts are underway for the IMM-BCP-01 trial.
IMM-ONC-01, targeting IL-38, is progressing towards an IND submission in the second half of 2022.
Focus remains on developing therapeutics for oncology and infectious diseases, including COVID-19.
Forward Guidance
Immunome is focused on advancing its platform and programs, including regulatory submissions, research, clinical trials, and strategic plans.
Positive Outlook
- Advancement of platform and programs
- Execution of regulatory plans
- Execution of research plans
- Execution of clinical plans
- Execution of strategic plans
Challenges Ahead
- Impact of the COVID-19 pandemic on business operations
- Differing interpretations and assessments of research and development data
- Ability to execute on strategy, including R&D efforts and regulatory filings
- Effectiveness of product candidates and potential inconsistency of preclinical and clinical trial data
- Emergence of further variants of concern
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...